Literature DB >> 9794564

Does long-term treatment of renal anaemia with recombinant erythropoietin influence oxidative stress in haemodialysed patients?

O Sommerburg1, T Grune, H Hampl, E Riedel, F J van Kuijk, J H Ehrich, W G Siems.   

Abstract

BACKGROUND: Patients with end-stage renal failure undergoing haemodialysis (HD) are exposed to oxidative stress. Increased levels of malondialdehyde (MDA) were demonstrated in plasma of uraemic patients, indicating accelerated lipid peroxidation (LPO) as a consequence of multiple pathogenetic factors. The aim of our investigation was to examine the role of renal anaemia in oxidative stress in HD patients.
METHODS: MDA and 4-hydroxynonenal (HNE) were measured in three groups of patients undergoing HD: group I comprised eight patients with a blood haemoglobin (Hb) < 10 g/dl (mean Hb = 8.1+/-1.3 g/dl), and group II were eight patients with a Hb > 10 g/dl (mean Hb=12.4+/-1.9g/dl); none of these 16 patients had been treated with human recombinant erythropoietin (rHuEpo). Group III comprised 27 patients with a mean Hb of 10.5+/-1.6 g/dl after long-term rHuEpo treatment.
RESULTS: Mean plasma concentrations of both MDA and HNE were significantly higher (P<0.0001) in all 43 HD patients than in 20 healthy controls (MDA 2.85+/-0.25 vs 0.37+/-0.03 microM, HNE 0.32+/-0.03 vs 0.10+/-0.01 microM). Comparing the three groups, it was shown that HD patients with a Hb <10 g/dl had significantly higher plasma levels of LPO products (MDA 3.81+/-0.86 microM, HNE 0.45+/-0.07 microM) than HD patients with a Hb >10g/dl (MDA 2.77+/-0.58 UM, HNE 0.25+/-0.05 microM), and than HD patients treated with rHuEpo (MDA 2.50+/-0.12 microM, HNE 0.29+/-0.03 microM). Furthermore, an inverse correlation between plasma concentration of LPO products and haemoglobin levels was seen (r=0.62, P<0.0001).
CONCLUSION: Radical generation in HD patients might be caused in part by renal anemia itself. Treatment with rHuEpo may decrease radical generation effectively in HD patients due to the increase in the number of red blood cells and blood haemoglobin concentration.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9794564     DOI: 10.1093/ndt/13.10.2583

Source DB:  PubMed          Journal:  Nephrol Dial Transplant        ISSN: 0931-0509            Impact factor:   5.992


  14 in total

Review 1.  Anemia and cardiovascular disease in diabetic nephropathy.

Authors:  Samy I McFarlane; Moro O Salifu; John Makaryus; James R Sowers
Journal:  Curr Diab Rep       Date:  2006-06       Impact factor: 4.810

2.  A lower level of reduced albumin induces serious cardiovascular incidence among peritoneal dialysis patients.

Authors:  Hiroyuki Terawaki; Yukie Matsuyama; Nanae Matsuo; Makoto Ogura; Jun Mitome; Akihiko Hamaguchi; Tomoyoshi Terada; Seiichi Era; Tatsuo Hosoya
Journal:  Clin Exp Nephrol       Date:  2012-02-23       Impact factor: 2.801

3.  Association of plasma ortho-tyrosine/para-tyrosine ratio with responsiveness of erythropoiesis-stimulating agent in dialyzed patients.

Authors:  Szilárd Kun; Esztella Mikolás; Gergo A Molnár; Eszter Sélley; Boglárka Laczy; Botond Csiky; Tibor Kovács; István Wittmann
Journal:  Redox Rep       Date:  2014-04-03       Impact factor: 4.412

4.  The antioxidant effect of erythropoietin on thalassemic blood cells.

Authors:  Johnny Amer; Mutaz Dana; Eitan Fibach
Journal:  Anemia       Date:  2010-12-21

Review 5.  Transcriptomics: A Step behind the Comprehension of the Polygenic Influence on Oxidative Stress, Immune Deregulation, and Mitochondrial Dysfunction in Chronic Kidney Disease.

Authors:  Simona Granata; Alessandra Dalla Gassa; Gloria Bellin; Antonio Lupo; Gianluigi Zaza
Journal:  Biomed Res Int       Date:  2016-06-21       Impact factor: 3.411

Review 6.  Modified Lipids and Lipoproteins in Chronic Kidney Disease: A New Class of Uremic Toxins.

Authors:  Nans Florens; Catherine Calzada; Egor Lyasko; Laurent Juillard; Christophe O Soulage
Journal:  Toxins (Basel)       Date:  2016-12-16       Impact factor: 4.546

7.  How the duration period of erythropoietin treatment influences the oxidative status of hemodialysis patients.

Authors:  Zorica M Dimitrijevic; Tatjana P Cvetkovic; Vidojko M Djordjevic; Dusica D Pavlovic; Nikola Z Stefanovic; Ivana R Stojanovic; Goran J Paunovic; Radmila M Velickovic-Radovanovic
Journal:  Int J Med Sci       Date:  2012-10-26       Impact factor: 3.738

8.  Serum Concentrations of F2-Isoprostanes and 4-Hydroxynonenal in Hemodialysis Patients in Relation to Inflammation and Renal Anemia.

Authors:  Ingrid Wiswedel; Daniela Peter; Andreas Gardemann; Francesco Carluccio; Hannelore Hampl; Werner Siems
Journal:  Biomark Insights       Date:  2008-05-27

Review 9.  Mitochondria: a new therapeutic target in chronic kidney disease.

Authors:  Simona Granata; Alessandra Dalla Gassa; Paola Tomei; Antonio Lupo; Gianluigi Zaza
Journal:  Nutr Metab (Lond)       Date:  2015-11-25       Impact factor: 4.169

10.  The Study of Hemodialysis Effectiveness on the Change Rate of Lipid Peroxidation and L-Carnitine Level in Hemodialysis Patients.

Authors:  Mohammad-Reza Safari; Maryam Isfahani; Nasrin Sheikh
Journal:  EJIFCC       Date:  2010-03-25
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.